AG百家乐在线官网

COVID-19: Banknote maker working on 'immunity certification' plans

Chief executive Clive Vacher said measures could include seals and codes to ensure vaccines are genuine.

Oxford vaccine may prevent infection from asymptomatic people
Image: Tests show the Oxford University vaccine is up to 90% effective
Why you can trust Sky News

Bank note maker De La Rue has revealed that it is in early discussions about working on COVID-19 "immunity certification schemes".

Clive Vacher, chief executive of the company - which as well as currency also makes authentication and security products - said he had been approached by governments and private companies.

He told the PA news agency that it was too early to say what would be required.

Please use Chrome browser for a more accessible video player

How the markets reacted to potential vaccine news

But possible products being discussed internally included "seals on vaccines and codes on vaccine vials that would ensure they are genuine".

Other measures could include holograms on certificates and services to track drugs through the supply chain.

De La Rue revealed as it published half-year results that it was "in early discussion regarding COVID-19 immunity certification schemes".

Mr Vacher told PA: "We have digital and physical products which would be well suited. But it's very early to say because we still don't know what a vaccine will look like.

More from Money

"We've had some conversations with some governments and private companies but it's far too early."

The disclosure came as De La Rue reported a pre-tax profit of £2.5m for the six months to 26 September compared to a loss of £12.1m a year earlier.

Please use Chrome browser for a more accessible video player

PM hopes for jab progress by Easter

It has been cutting costs and reducing debts as part of a three-year turnaround plan.

The company recently won an extension in its contract to print banknotes for the Bank of England until 2028.

Its comments on a potential COVID immunity certificate scheme come after the latest positive update this week on vaccine developments - with tests showing the Oxford University vaccine being produced by AstraZeneca is up to 90% effective.